Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Characterization of the serotonin 2A receptor selective PET tracer (R)-[18F]MH.MZ in the human brain

Research output: Contribution to journalJournal articleResearchpeer-review

  1. High nodal FDG uptake increases risk of distant metastasis in patients with oropharyngeal squamous cell carcinoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Assessment of acute bone loading in humans using [18F]NaF PET/MRI

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. 18F FDG-PET/CT has poor diagnostic accuracy in diagnosing shoulder PJI

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Feasibility of multi-parametric PET and MRI for prediction of tumour recurrence in patients with glioblastoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Imaging HDACs In Vivo: Cross-Validation of the [11C]Martinostat Radioligand in the Pig Brain

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Dynamic coupling of whole-brain neuronal and neurotransmitter systems

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Serotonin release measured in the human brain: a PET study with [11C]CIMBI-36 and d-amphetamine challenge

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

PURPOSE: The serotonin receptor subtype 2A antagonist (5-HT2AR) (R)-[18F]MH.MZ has in preclinical studies been identified as a promising PET imaging agent for quantification of cerebral 5-HT2ARs. It displays a very similar selectivity profile as [11C]MDL 100907, one of the most selective compounds identified thus far for the 5-HT2AR. As [11C]MDL 100907, (R)-[18F]MH.MZ also displays slow brain kinetics in various animal models; however, the half-life of fluorine-18 allows for long scan times and consequently, a more precise determination of 5-HT2AR binding could still be feasible. In this study, we aimed to evaluate the potential of (R)-[18F]MH.MZ PET to image and quantify the 5-HT2AR in the human brain in vivo.

METHODS: Nine healthy volunteers underwent (R)-[18F]MH.MZ PET at baseline and four out of these also received a second PET scan, after ketanserin pretreatment. Regional time-activity curves of 17 brain regions were analyzed before and after pretreatment. We also investigated radiometabolism, time-dependent stability of outcomes measures, specificity of (R)-[18F]MH.MZ 5-HT2AR binding, and performance of different kinetic modeling approaches.

RESULTS: Highest uptake was determined in 5-HT2AR rich regions with a BPND of approximately 1.5 in cortex regions. No radiometabolism was observed. 1TCM and 2TCM resulted in similar outcome measure, whereas reference tissue models resulted in a small, but predictable bias. (R)-[18F]MH.MZ binding conformed to the known distribution of 5-HT2AR and could be blocked by pretreatment with ketanserin. Moreover, outcomes measures were stable after 100-110 min.

CONCLUSION: (R)-[18F]MH.MZ is a suitable PET tracer to image and quantify the 5-HT2AR system in humans. In comparison with [11C]MDL 100907, faster and more precise outcome measure could be obtained using (R)-[18F]MH.MZ. We believe that (R)-[18F]MH.MZ has the potential to become the antagonist radiotracer of choice to investigate the human 5-HT2AR system.

Original languageEnglish
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume47
Issue number2
Pages (from-to)355-365
Number of pages11
ISSN1619-7070
DOIs
Publication statusPublished - Feb 2020

ID: 59790283